A phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC)

M. Hidalgo, R. Epelbaum, B. M. Wolpin, S. M. Stemmer, R. Geva, T. Golan, E. Borazanci, M. Borad, K. S. Pedersen, J. O. Park, R. Ramirez, A. Peled, T. M. Lustig, O. Bohana Kashtan, O. Rosenfeld, E. Sorani, K. Schlienger, A. Vainstein Haras, D. D. Von Hoff

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)viii402
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
StatePublished - Oct 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Hidalgo, M., Epelbaum, R., Wolpin, B. M., Stemmer, S. M., Geva, R., Golan, T., Borazanci, E., Borad, M., Pedersen, K. S., Park, J. O., Ramirez, R., Peled, A., Lustig, T. M., Bohana Kashtan, O., Rosenfeld, O., Sorani, E., Schlienger, K., Vainstein Haras, A., & Von Hoff, D. D. (2018). A phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC). Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii402. https://doi.org/10.1093/annonc/mdy288.006